- Home
- Patient & Visitors
- Research & Clinical Trials
- Find Clinical Trials
Find Clinical Trials
Current Clinical Trials
Breast
| Title | Status |
|---|---|
|
Pembrolizumab in Treating Patients with Triple-Negative Breast Cancer Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
|
Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
|
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
|
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Principal Investigator: Michael Wahl, MD |
Click here for more information on this trial. |
Lung
| Title | Status |
|---|---|
|
Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
|
Crizotinib in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
|
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
|
Nivolumab After Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer (ANVIL) Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
|
Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Principal Investigator: Michael Wahl, MD |
Click here for more information on this trial. |
|
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
|
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
|
A Phase 3 Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab Principal Investigator: David Hufnagel, DO |
Hematology
| Disease Site | Title | Status |
|---|---|---|
| Myelofibrosis and Essential Thrombocythemia |
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) Principal Investigator: Ike Onwere, MD |
Click here for more information on this trial. |
| Paroxysmal Nocturnal Hemoglobynuria |
Study to Evaluate the Efficacy and Safety of APL-2 in Patients with PNH Principal Investigator: Farnoush Abar, MD |
Click here for more information on this trial. |
| Multiple Myeloma |
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Principal Investigator: Farnoush Abar, MD |
Click here for more information on this trial. |
Other
| Disease Site | Title | Status |
|---|---|---|
| Advanced Cancers |
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma Principal Investigator: Wei Bai, MD |
Click here for more information on this trial. |
| Bladder |
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
| Head and neck |
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients with Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin Principal Investigator: David Hufnagel, DO |
Click here for more information on this trial. |
To learn more about cancer clinical trials available, visit clinicaltrials.gov.
| Disease Site | Title | Status |
|---|---|---|
| Patients with Heart Failure, but Preserved Ejection Fraction |
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PARALLAX) Principal Investigator: Sridhar Vijayasekaran, MD |
Click here for more information on this trial. |
| Patients not responding to Cardiac Resynchronization Therapy |
MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing (MORE-CRT MPP) Principal Investigator: Jeff Hsing, MD |
Click here for more information on this trial. |
| PUMA-NER-6201: A Study Looking at the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide |
| PUMA-NER-6201: A Study Looking at the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and L |
| Disease Site | Title | Status |
|---|---|---|
| Invasive Fungal Infections Registry (Not a treatment trial) |
Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles Principal Investigator: Sugat Patel, MD |
Click here to learn more about this trial. |
| Disease Site | Title | Status |
|---|---|---|
| Ankylosing Spondylitis |
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap) Principal Investigator: Jonathan Jones, MD |
Click here for more information on this trial. |
| Condition | Title | Status |
|---|---|---|
| Insulin Sensitivity, Obesity and Sedentary Lifestyle |
Exercise and Insulin Signaling in Human Skeletal Muscle
|
Click here for more information on this trial or review an informational flyer. |
For more information about clinical research at Samaritan, contact us at 541-768-4352 or clinicalresearch@samhealth.org.